Skip to main content

Press releases | December 12, 2020

Fried Frank acted as counsel to BofA Securities as financial advisor to Alexion in its US$39b definitive agreement to be acquired by AstraZeneca. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery and development and commercialization of life-changing medicines. AstraZeneca is a global biopharmaceutical company that develops prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The boards of directors of both companies have unanimously approved the acquisition. The Fried Frank deal team was led by corporate partner Philip Richter and included corporate partner Ian Lopez, special counsel Roy Tannenbaum, and corporate associate Clayton Mark.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.